MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
Key Details
- 1Proton therapy controls leptomeningeal metastasis, with patients living over twice as long versus conventional radiation.
- 2Randomized phase 2 trial: proton craniospinal therapy offers stability >3x longer for LM compared to standard radiation.
- 3Study funded by PCORI explores LLM-based PainReporter model to summarize cancer patient pain experiences from narrative notes.
- 4Research on tumor genetics and location finds SMAD4 reactivation suppresses liver metastases but increases lung metastases.
- 5Regulatory T cells, via enkephalin, regulate pain/inflammation in skin neuronal circuits.
Why It Matters
Advances in radiotherapeutic options like proton therapy improve outcomes in difficult cancer metastasis scenarios. Testing LLMs for summarising patient pain could impact clinical workflow, interpretation, and the integration of AI into patient care.
Source
EurekAlert
Related News
•EurekAlert
Imaging AI Tool Predicts MS Drug Response Using Cell Morphology
Brazilian and French researchers have developed an imaging-based AI tool to predict how multiple sclerosis patients will respond to natalizumab treatment.
•EurekAlert
MD Anderson Highlights Imaging AI and Proton Therapy Trends Before 2025 ASTRO
MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
•EurekAlert
$16M PRISM Trial Launches to Evaluate AI in Breast Cancer Mammography
A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.